Mark Krul

We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate®. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling expertise and capabilities, robust assays, and high-throughput screening possibilities forms the core of our contribution. Our offering varies from long-term drug discovery partnerships, (custom) model & assay development services compound screening, to off-the-shelf products. For more information, visit: www.mimetas.com.

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products. Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.

We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate®. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling expertise and capabilities, robust assays, and high-throughput screening possibilities forms the core of our contribution. Our offering varies from long-term drug discovery partnerships, (custom) model & assay development services compound screening, to off-the-shelf products. For more information, visit: www.mimetas.com.

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products. Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.